Psychemedics Past Earnings Performance
Past criteria checks 0/6
Psychemedics's earnings have been declining at an average annual rate of -34.6%, while the Healthcare industry saw earnings growing at 5.3% annually. Revenues have been declining at an average rate of 9.5% per year.
Key information
-34.6%
Earnings growth rate
-33.6%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | -9.5% |
| Return on equity | -55.0% |
| Net Margin | -14.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares
Jul 29
There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump
Jan 08Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07
May 13Psychemedics GAAP EPS of -$0.06, revenue of $6.51M
Aug 09Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play
Apr 25Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend
Nov 18Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target
Oct 18Psychemedics reports Q1 results
May 10We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope
May 07Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt
Mar 05Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)
Jan 30How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?
Jan 11Psychemedics reports Q3 results
Nov 09Revenue & Expenses Breakdown
How Psychemedics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 20 | -3 | 10 | 1 |
| 30 Jun 24 | 21 | -5 | 10 | 1 |
| 31 Mar 24 | 22 | -4 | 10 | 1 |
| 31 Dec 23 | 22 | -4 | 10 | 1 |
| 30 Sep 23 | 23 | -4 | 10 | 1 |
| 30 Jun 23 | 24 | -2 | 9 | 1 |
| 31 Mar 23 | 25 | -2 | 9 | 1 |
| 31 Dec 22 | 25 | -1 | 9 | 1 |
| 30 Sep 22 | 26 | -2 | 10 | 1 |
| 30 Jun 22 | 26 | -1 | 9 | 1 |
| 31 Mar 22 | 26 | -1 | 9 | 1 |
| 31 Dec 21 | 25 | -1 | 9 | 1 |
| 30 Sep 21 | 24 | 0 | 8 | 1 |
| 30 Jun 21 | 22 | -1 | 8 | 1 |
| 31 Mar 21 | 20 | -4 | 9 | 1 |
| 31 Dec 20 | 21 | -4 | 10 | 1 |
| 30 Sep 20 | 25 | -4 | 11 | 1 |
| 30 Jun 20 | 29 | -2 | 11 | 1 |
| 31 Mar 20 | 35 | 1 | 11 | 1 |
| 31 Dec 19 | 38 | 2 | 12 | 2 |
| 30 Sep 19 | 39 | 3 | 11 | 2 |
| 30 Jun 19 | 40 | 4 | 11 | 2 |
| 31 Mar 19 | 42 | 4 | 11 | 2 |
| 31 Dec 18 | 43 | 5 | 11 | 2 |
| 30 Sep 18 | 42 | 6 | 11 | 1 |
| 30 Jun 18 | 42 | 6 | 11 | 1 |
| 31 Mar 18 | 40 | 6 | 11 | 1 |
| 31 Dec 17 | 40 | 6 | 10 | 1 |
| 30 Sep 17 | 41 | 6 | 10 | 1 |
| 30 Jun 17 | 43 | 7 | 10 | 1 |
| 31 Mar 17 | 43 | 8 | 10 | 1 |
| 31 Dec 16 | 39 | 7 | 10 | 1 |
| 30 Sep 16 | 34 | 5 | 10 | 1 |
| 30 Jun 16 | 30 | 3 | 10 | 1 |
| 31 Mar 16 | 27 | 1 | 10 | 2 |
| 31 Dec 15 | 27 | 2 | 10 | 2 |
| 30 Sep 15 | 28 | 2 | 10 | 2 |
| 30 Jun 15 | 28 | 2 | 9 | 2 |
| 31 Mar 15 | 29 | 3 | 9 | 1 |
| 31 Dec 14 | 29 | 3 | 9 | 1 |
| 30 Sep 14 | 29 | 3 | 9 | 1 |
| 30 Jun 14 | 28 | 4 | 9 | 1 |
| 31 Mar 14 | 27 | 4 | 9 | 1 |
| 31 Dec 13 | 27 | 4 | 9 | 1 |
Quality Earnings: PMD is currently unprofitable.
Growing Profit Margin: PMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PMD is unprofitable, and losses have increased over the past 5 years at a rate of 34.6% per year.
Accelerating Growth: Unable to compare PMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).
Return on Equity
High ROE: PMD has a negative Return on Equity (-54.99%), as it is currently unprofitable.